Analysts Estimate Buzz in Focus: Huntington Bancshares (NASDAQ:HBAN), American Express (NYSE:AXP)

Huntington Bancshares Incorporated (NASDAQ:HBAN) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -1.53% to $13.52. The HBAN held a rough session during the week but was ready to get some critical analysis. The stock was assessed by a pool of analysts at WSJ and came out with some serious outcomes not to be avoided before making investment. The HBAN ratings chart showed that 17 gave HOLD ratings for the current month as 1 analyst opting for Overweight option for same period, whereas, 1 analyst out of pool gave UNDERWEIGHT rating. For stocks’ current month, 8 analysts opted for BUY ratings. The stock price target chart showed average price target of 14.78 as compared to current price of 13.52.

Taking look on per share earnings estimates, its next year first quarter current estimate trend for EPS was for $0.23 and on annual basis FY 2016 estimate trends at current was for $0.94 as compared to one month ago of $0.94, and for next year per share earnings estimates have $1.10.

The share price of HBAN attracts active investors, as stock price of week volatility recorded 2.01%. The stock is going forward to its 52-week low with 71.16% and lagging behind from its 52-week high price with -7.75%.

American Express Company (NYSE:AXP) [Trend Analysis] moved down reacts as active mover, shares a decrease -0.50% to traded at $78.85 and the percentage gap between open changing to regular change was -0.13%. Lets us look over what analysts have to say about performance of the AXP. Starting with EPS for the final quarter of this year. EPS is usually the indicator of profitability for the company. According to WSJ analysis, the Q4 2016 current estimates trends were for $1.29 as compared to the next year Q1 current trend of $1.41. While on annual basis the current EPS estimates trend for FY 2017 came in for $6.29 as compared to three months ago $6.28.

The stock prices target chart showed high target of 97 kept by analysts at WSJ while the average price target was for 81 as compared to current price of 78.85. Somehow, the stock managed to gain BUY ratings by 9 analysts in current tenure as 1 analyst having overweight ratings, 17 recommend as HOLD, 1 stands at Underweight and 4 gave it as a SELL security for current period. Overall, the consensus ratings were for Hold by the pool of analysts.

The firm past twelve months price to sales ratio was 2.21 and price to cash ratio remained 22.02. As far as the returns are concern, the return on equity was recorded as 25.50% and return on investment was 4.20% while its return on asset stayed at 3.40%. The firm has total debt to equity ratio measured as 5.15.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *